TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05451888

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spa treatment
Description: A 40 minute period of lying in the spa treatment pool
Study: NCT05063370

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levosimendan
Description: Patients will receive Levosimendan infusion 12 hours before surgery in the ICU at a dose of 0.2 μg kg/min for the first hour and then reduced to 0.1 μg kg/ min to be continued in the operating room and then in the ICU (total infusion time of 24 hours).

Intervention type: DRUG
Group type: OTHER
Intervention: Standard Care
Description: Patients will not receive Levosimendan and will receive standard care according to the institution protocol
Study: NCT06493942

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BioCoat® by Premier®
Description: BioCoat is a 56% filled resin formula that provides added strength and excellent long-term resistance to wear ؤomparable to flowable composites.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: UltraSeal XT™ plus by Ultradent
Description: UltraSeal XT plus is a 58%-filled resin fluoride-releasing sealant. It is strong and has high wear resistant
Study: NCT05320588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIO-106
Description: BIO-106 is a novel antibody-drug conjugate (ADC) that targets the human trophoblast cell surface antigen 2 (Trop-2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIO-106
Description: BIO-106 is a novel antibody-drug conjugate (ADC) that targets the human trophoblast cell surface antigen 2 (Trop-2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Programmed death receptor-1 (PD 1)-blocking antibody
Study: NCT06158880

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcoholic Beverage
Description: Participants will consume an alcoholic beverage (vodka mixed with fruit juice) that is the equivalent of 3-4 standard alcoholic drinks based on their body weight.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-alcoholic Beverage
Description: Participants will consume a nonalcoholic beverage (fruit juice) that is the isovolemic equivalent of 3-4 standard alcoholic drinks based on their body weight.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partner Negative Mood Manipulation
Description: Participants will engage in a laboratory task and will then report their own and their partner's emotions following the task.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Partner Positive Mood Manipulation
Description: Participants will engage in a laboratory task and will then report their own and their partner's emotions following the task.
Study: NCT05316987

Intervention type: RADIATION
Group type: OTHER
Intervention: Narrow band ultraviolet B
Description: 48 sessions of narrow band ultraviolet
Study: NCT04700462

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sm-EMA
Description: Self-monitoring ecological momentary assessment behavior change tool to promote adherence to a desired behavior (i.e. COVID-19 preventative behaviors).
Study: NCT05426343

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVC-COV1901
Description: Approximately 125 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AZD1222
Description: Approximately 125 participants will receive 2 doses of AZD1222 at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
Study: NCT05246410

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spot stent system
Description: Spot stent system designed and produced by Acotec

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Self-expanding peripheral stent system
Description: Self-expanding peripheral stent system designed and produced by Ev3, Inc
Study: NCT05144022

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Bungee jump
Description: Bungee jump from a cran

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bungee jump
Description: Bungee jump from a cran
Study: NCT06394063

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Telitacicept
Description: Telitacicept 160 mg SC every other week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to Telitacicept
Study: NCT06513702

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transesophageal lung ultrasound (TELUS) guided recruitment maneuver
Description: 1. Lung reinflation guided by transesophageal lung ultrasound (TELUS) after cardiopulmonary bypass weaning~2. TELUS guided recruitment maneuver with continuous positive pressure of 30cmh20 for 20 seconds and 40cmh20 for 20 seconds during sternal wiring

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual bag lung reinflation
Description: After weaning of CPB, Lung will be reinflated by 5 deep manual bag infaltion until full inflation observed by the anesthetist.~During sternal wiring, Lung ultrasound will be examine - LUNG ultrasound score will be taken- no recruitment maneuver will be done in this contro group (Basically this group of patient is a routine practice in cardiac surgery
Study: NCT06449625

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide Pen Injector [Ozempic]
Description: Semaglutide active drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: semaglutide placebo
Study: NCT04987203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib
Description: Tivozanib will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib
Description: Tivozanib will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered via intravenous infusion.
Study: NCT04652934

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurodynamic
Description: The Upper Limb Neurodynamic Test (ULNT1) technique described by Butler will be performed on the affected limb. This technique consists of performing shoulder depression, 90º shoulder abduction, hand, wrist and forearm in a neutral position, external rotation of the shoulder and extension of the elbow. After positioning the limb in this position, wrist flexion-extension movements will be performed smoothly and rhythmically of 20 movements every minute, for 3 minutes, three times per session with 1 minute of rest between each series.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Mimic group
Description: The protocol used by Beneciuk et al. Will be used. This intervention consists of imitating NM without stressing the nervous system. It will be carried out as follow: a neutral cervical position will be maintained (0º of cervical inclination), 45º of shoulder abduction without depression, 45º of external rotation of the shoulder combined with 45º of elbow flexion with the forearm in pronation. Afterwards, 10 wrist flexion-extension movements will be performed at a rate of 6 seconds per cycle (3 seconds of flexion and 3 seconds of extension). The resistance that you will feel will stabilize when you change motion. Once the 10 cycles of movements have been carried out, a wrist flexion will be maintained for 10 seconds.
Study: NCT06411821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulixertinib
Description: 300 mg twice daily, for every 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulixertinib
Description: 300 mg twice daily, for every 28-day cycle.
Study: NCT05498272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 300 mg orally twice a day (D1-D30) for 6 Cycles (30 day Cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHRH agonist
Description: Total duration of therapy will be for 180 days with use of agent as per institutional standards
Study: NCT05815810

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Attuned: A mobile application
Description: Subjects will undergo voice and communication modification therapy via the Attuned application. This consists of an 11 week program consisting of different modules to learn how to modify voice (e.g., pitch, intonation, resonance). At the end of each module, participants will be given exercises to practice what they learned.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In-Person Voice Modification Therapy
Description: Subjects will undergo standard of care in-person voice modification therapy at Ithaca College.
Study: NCT02974582

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to smoking advertising with coupon
Description: Direct mail marketing of smoking advertising with discount coupon

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to smoking advertising without coupons
Description: Direct mail marketing of smoking advertising without discount coupon

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to non health related images
Description: Control group

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to non health related images
Description: Control group
Study: NCT06173791

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DFDBA fibers
Description: Bone Allograft fibers used in dental sinus reconstruction surgery

Intervention type: DEVICE
Group type: OTHER
Intervention: DFDBA particles
Description: Bone Allograft particles used in dental sinus reconstruction surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DBBM
Description: DBBM is routinely used in sinus augmentation to support dental implant placement and restoration of missing teeth.

Intervention type: DEVICE
Group type: OTHER
Intervention: DBBM
Description: DBBM is routinely used in sinus augmentation to support dental implant placement and restoration of missing teeth.
Study: NCT06061471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK111
Description: AK111 regimen 1-subcutaneous injection,until week 24.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK111
Description: AK111 regimen 2-subcutaneous injection,until week 24.
Study: NCT06254924

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: QI App Users
Description: QI App users will be asked to complete a daily, 2-question mood and stress survey. They will be encouraged to use the QI App to practice mindfulness skills including meditation, drawing, coloring, breathing, and walking. They will be encouraged to use the QI App to help them participate in asynchronous group running activities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parents/Guardians of QI App Users
Description: Parents/Guardians of QI App users will be informed that their child is using the QI App for a 6-week period.
Study: NCT06056973

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: jinghua weikang capsule
Description: Oral Jinghua Weikang Capsule, two capsules each time, three times a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: jinghua weikang capsule
Description: Oral Jinghua Weikang Capsule, two capsules each time, three times a day
Study: NCT05158348

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine Hydrochloride
Description: Group A will receive post-operative nebulised dexametomidine and lidocaine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebulized lidocaine
Description: Group B will receive post-operative will receive nebulised lidocaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local infiltration of lidocaine
Description: group C will receive intra-operative local infiltration of lidocaine
Study: NCT05430867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine Oral Tablet
Description: Memantine 20mg once-daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine Oral Tablet
Description: Memantine 20mg once-daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GV-971 capsule
Description: GV-971 450mg twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GV-971 capsule
Description: GV-971 450mg twice a day
Study: NCT05954754

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragmatic Breathing Exercises
Description: Diaphragmatic breathing exercise training was given individually to each pregnant women in the experimental group by one of the trained researchers. Two weeks after the first application, the researcher made the pregnant woman repeat the application 2 days a week via video call. Thus, a total of five diaphragmatic breathing exercises were applied to pregnant women in the experimental group during two weeks. They continued to do breathing exercises for 20-30 minutes a day for ten minutes each day for two weeks as they could tolerate.
Study: NCT04974307

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OrCam MyEye 2
Description: The OrCam MyEye 2 is a 22.5-g portable, eyeglass-mounted device that converts camera-captured inputs to auditory outputs. Its advertised functions include text reading, facial recognition, and product identification.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OrCam MyEye 2
Description: The OrCam MyEye 2 is a 22.5-g portable, eyeglass-mounted device that converts camera-captured inputs to auditory outputs. Its advertised functions include text reading, facial recognition, and product identification.
Study: NCT06004661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAA617
Description: Administered intravenously once every cycles (1 cycle = 6 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-11
Description: Single intravenous dose of approximately 150 MBq
Study: NCT05446298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONC-392
Description: ONC-392 will be given by IV infusion, q3w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONC-392
Description: ONC-392 will be given by IV infusion, q3w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab in fixed dose of 200 mg will be given by IV infusion, q3w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab in fixed dose of 200 mg will be given by IV infusion, q3w.
Study: NCT05911321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Pharmaceutical form: Solution for infusion. Route of administration: Intravenous 10 mg/kg will be administered intravenously once weekly during cycle 1 and every other week during each subsequent cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pharmaceutical form: Pill for oral use. Route of administration: 3 mg Pomalidomide 3 mg pill will be taken by mouth once daily on days 1-21 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Pharmaceutical form: Tablet for oral use Route of administration: Pill for oral use. Dexamethasone 20 mg tablet will be taken by mouth once per week.
Study: NCT06008704

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Clinical assessment
Description: The clinical assessment consists on behavioural and motor evaluations to determine the characteristics of the population

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Clinical assessment
Description: The clinical assessment consists on behavioural and motor evaluations to determine the characteristics of the population

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Pain characteristics assessment
Description: The pain characteristics assessment will be made with a variety of scales and questionnaires which allow to identify the extent of central pain and functional impairment

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Pain characteristics assessment
Description: The pain characteristics assessment will be made with a variety of scales and questionnaires which allow to identify the extent of central pain and functional impairment

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MRI
Description: The MRI examination allows anatomical imaging, diffusion imaging and functional imaging to measure specific markers

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MRI
Description: The MRI examination allows anatomical imaging, diffusion imaging and functional imaging to measure specific markers

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Thermotest
Description: The thermotest is performed to assess the pain perception threshold

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Thermotest
Description: The thermotest is performed to assess the pain perception threshold

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: UPDRS-III Scale
Description: The UPDRS-III scale allows to asses motor functionality of PD patients

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: UPDRS-III Scale
Description: The UPDRS-III scale allows to asses motor functionality of PD patients

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: [18F]-MPPF PET scan
Description: The PET scan after injection of \[18F\]-MPPF at a dose of 200 Megabecquerel/kg +/-10% allows in vivo imaging of 5HT1A receptors

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: [18F]-MPPF PET scan
Description: The PET scan after injection of \[18F\]-MPPF at a dose of 200 Megabecquerel/kg +/-10% allows in vivo imaging of 5HT1A receptors
Study: NCT06664502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EYE201
Description: EYE201 solution for intravitreal administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EYE201
Description: EYE201 solution for intravitreal administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EYE201
Description: EYE201 solution for intravitreal administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EYE201
Description: EYE201 solution for intravitreal administration
Study: NCT05139524

Intervention type: OTHER
Intervention: Evidence of past or recent RVF exposure
Description: Detection of RVF exposure.
Study: NCT06604026

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BD PosiFlush™ SafeScrub
Description: Clinicians will be advised to use BD PosiFlush™ SafeScrub as per the Instructions for Use for the treatment arm of the study.~An independent nurse observer will observe and document any adverse events (e.g.~local skin reaction, or irritation, or allergic response, up to and including symptoms of anaphylaxis), compliance with needleless access device scrubbing before flushing, device success rate (encapsulation and removal) as well as the time requirements and number of steps for needleless access device scrubbing prior to catheter flushes during medication administration process.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BD PosiFlush™
Description: Clinicians will be advised to follow and document the respective unit protocol, while using the standard pre-filled syringe (BD PosiFlush™ SP Syringe) and alcohol pad for scrubbing and flushing of NADs in the control arm of the study as the routine practice.~An independent nurse observer will observe and document any adverse events (e.g.~local skin reaction, or irritation, or allergic response, up to and including symptoms of anaphylaxis), compliance with needleless access device scrubbing before flushing, device success rate (encapsulation and removal) as well as the time requirements and number of steps for needleless access device scrubbing prior to catheter flushes during medication administration process.
Study: NCT06660368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen
Description: Filgrastim/G-CSF 300 mcg/day for 6 days beginning 24 hours prior to multiagent chemotherapy (days 0-5), cladribine 5 mg/m2 given intravenously over 2 hours for 5 consecutive days (days 1-5), cytarabine given IV over 4 hours for 5 consecutive days (days 1-5) beginning 2 hours after the completion of cladribine, and mitoxantrone 16 mg/m2 given intravenously over 30 minutes for 3 days (days 1-3) after completion of cytarabine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen
Description: Filgrastim/G-CSF 300 mcg/day for 6 days beginning 24 hours prior to multiagent chemotherapy (days 0-5), cladribine 5 mg/m2 given intravenously over 2 hours for 5 consecutive days (days 1-5), cytarabine given IV over 4 hours for 5 consecutive days (days 1-5) beginning 2 hours after the completion of cladribine, and mitoxantrone 16 mg/m2 given intravenously over 30 minutes for 3 days (days 1-3) after completion of cytarabine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be administered orally, once daily, with food.
Study: NCT06660069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stannous Fluoride Toothpaste (Parodontax Complete Protection Toothpaste)
Description: Toothpaste containing 0.454 percent (%) weight by weight (w/w) SnF2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPC Mouthwash (Parodontax Active Gum Health Mouthwash)
Description: Mouthwash containing 0.07% w/w CPC.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regular Fluoride Toothpaste (Crest Cavity Protection)
Description: Toothpaste containing 0.243% w/w sodium fluoride.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stannous Fluoride Toothpaste (Parodontax Complete Protection Toothpaste)
Description: Toothpaste containing 0.454% w/w SnF2.
Study: NCT06675331

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medically Tailored Meal Program with Traditional Navajo Foods
Description: Patients will receive medically-tailored meals incorporating local traditional Navajo foods
Study: NCT06602544

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic Apparel
Description: A robotic apparel system is a portable, lightweight textile-based wearable robot that is worn around the waist and thighs. The apparel provides assistive flexion moment about the hip joint during the swing phase of gait by spooling in a cable that connects the thigh wraps to the front of the waist belt. Inertial measurement units embedded in the thigh wraps are used to control the timing of the robotic apparel assistance. Robotic apparel assistance magnitude is delivered as a small percentage of the bodyweight of the wearer.
Study: NCT05239585

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epilog device
Description: Pilot the use of wireless EEG technology in neonates with mild neonatal encephalopathy and neonates with spells to see if this device can be used to determine the risk for neonatal seizure and need for escalation of care and full scalp EEG
Study: NCT06679309

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated care plan
Description: Complex care plan facilitated by the integrated care lead with 90 day follow-up, 24/7 phone support and connection with resources and services